ZYDUS LIFESCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 989.8 INR | +0.78% |
|
-0.69% | +43.72% |
| 02:02am | Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets | MT |
| 05-10 | India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 11.83B | ||||||
| 43.27B | ||||||
| 22.92B | ||||||
| 15.43B | ||||||
| 12.95B | ||||||
| 6.91B |
